Declaration of Interest



A. General Information

Full Name: Peter Juni

Date (MM/DD/YYYY): 2/12/2021

What is the nature of your role in the Drugs & Biologics Clinical Practice Guidelines Working Group: Member

B. Declaration of Interest

Please fill out the following table by indicating whether you or your institution have received compensation, regardless of the amount, in the form of payment or services, from entities in the health care, public health, or other related arenas that could be perceived to influence your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group, or related aspects. Please report all compensation that has been received in the last 3 years prior to your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group.

If you have selected 'Yes' for any of the categories below, please indicate whether the compensation is related to COVID-19 or not, the name of the entity providing the compensation, and an explanation. If you have more than one relationship for each Category, please ensure to include all of them by selecting the '+' sign at the end of each row.

Category	No	Yes, paid to you	Yes, paid to your institution	Related to COVID-19?		Entity	Explanation
				No	Yes	,	
Grant			\boxtimes	\boxtimes		Canadian Institutes of Health Research (CIHR)	This is a grant to the institution under the Canada Research Chairs Program (Peter Jüni is a Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases)
Consulting				\boxtimes		Amgen	Honoraria to the institution for participation in advisory board
Consulting			\boxtimes	\boxtimes		Ava	Honoraria to the institution for participation in advisory board
Consulting				\boxtimes		Fresenius	Honoraria to the institution for participation in advisory board
Board membership	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Employment	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Payment for lectures including service on speaker bureaus						Interaction 2019	Interaction 2019 speaker honorarium

					Sept 21, 2019 ('clinical research' talk)
Payment for manuscript preparation	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Patents	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Royalties	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Payment for development of educational presentations	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Payment for writing or reviewing any reports or publications	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Provision of writing assistance, equipment, software, or administrative support	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Expert testimony	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Stock/stock options	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Support for travel/accommodations/ meeting expenses		\boxtimes	\boxtimes	Amgen	Travel expenses for participation in advisory board meetings
Support for travel/accommodations/ meeting expenses		\boxtimes	\boxtimes	Fresenius	Travel expenses for participation in advisory board meetings

C. Other Relationships

Are there any other relationships or activities that could be perceived to influence your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group (COVID-19 related or not)? Please select one of the following:

- ☑ No, there are no other relationships/conditions/circumstances that present, or may be perceived to present, a
 potential conflict of interest.
- ☐ Yes, there are relationships/conditions/circumstances that present, or may be perceived to present, a potential conflict of interest.

If you have selected 'Yes', use the following table to indicate whether the relationship is related to COVID-19 or not, provide the name of the entity (if applicable), and an explanation describing the nature of the relationship. If you have more than one relationship, please ensure to include all of them by selecting the '+' sign at the end of each row.

Category	Related to COVID-19?		Entity	Explanation	
Guitago. y	No	Yes	.		
Relationship			Click or tap here to enter text.	Click or tap here to enter text.	

D. Acknowledgement

I certify that the above information contained in this Declaration of Interest is true and correct to the best of my knowledge. If any matter that gives rise to, or may be perceived to give rise to, a conflict of interest during my participation in the Drugs & Biologics Clinical Practice Guidelines Working Group, I will promptly notify the co-Chairs of the Drugs & Biologics Clinical Practice Guidelines Working Group, and provide an updated Declaration of Interest.

Full Name: Peter Juni

Date (MM/DD/YYYY): 2/12/2021